169 related articles for article (PubMed ID: 17680242)
1. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
Wieder HA; Ott K; Lordick F; Becker K; Stahl A; Herrmann K; Fink U; Siewert JR; Schwaiger M; Weber WA
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1925-32. PubMed ID: 17680242
[TBL] [Abstract][Full Text] [Related]
2. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis.
Zhu W; Xing L; Yue J; Sun X; Sun X; Zhao H; Yu J
Br J Radiol; 2012 Sep; 85(1017):e694-701. PubMed ID: 22337686
[TBL] [Abstract][Full Text] [Related]
4. [
Harustiak T; Zemanova M; Fencl P; Hornofova L; Pazdro A; Snajdauf M; Salkova E; Lischke R; Stolz A
Br J Surg; 2018 Mar; 105(4):419-428. PubMed ID: 29417984
[TBL] [Abstract][Full Text] [Related]
5. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
[TBL] [Abstract][Full Text] [Related]
6. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
[TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.
Ott K; Weber WA; Fink U; Helmberger H; Becker K; Stein HJ; Müller J; Schwaiger M; Siewert JR
World J Surg; 2003 Sep; 27(9):1035-9. PubMed ID: 12917760
[TBL] [Abstract][Full Text] [Related]
8. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
Ott K; Weber WA; Lordick F; Becker K; Busch R; Herrmann K; Wieder H; Fink U; Schwaiger M; Siewert JR
J Clin Oncol; 2006 Oct; 24(29):4692-8. PubMed ID: 16966684
[TBL] [Abstract][Full Text] [Related]
9. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
Wieder HA; Brücher BL; Zimmermann F; Becker K; Lordick F; Beer A; Schwaiger M; Fink U; Siewert JR; Stein HJ; Weber WA
J Clin Oncol; 2004 Mar; 22(5):900-8. PubMed ID: 14990646
[TBL] [Abstract][Full Text] [Related]
10. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
11. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
Weber WA; Ott K; Becker K; Dittler HJ; Helmberger H; Avril NE; Meisetschläger G; Busch R; Siewert JR; Schwaiger M; Fink U
J Clin Oncol; 2001 Jun; 19(12):3058-65. PubMed ID: 11408502
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
[TBL] [Abstract][Full Text] [Related]
13. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
14. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
15. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
[TBL] [Abstract][Full Text] [Related]
16. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
Lordick F
Recent Results Cancer Res; 2012; 196():201-11. PubMed ID: 23129376
[TBL] [Abstract][Full Text] [Related]
17. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.
Wieder HA; Beer AJ; Lordick F; Ott K; Fischer M; Rummeny EJ; Ziegler S; Siewer JR; Schwaiger M; Weber WA
J Nucl Med; 2005 Dec; 46(12):2029-34. PubMed ID: 16330567
[TBL] [Abstract][Full Text] [Related]
18. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).
Klaeser B; Nitzsche E; Schuller JC; Köberle D; Widmer L; Balmer-Majno S; Hany T; Cescato-Wenger C; Brauchli P; Zünd M; Pestalozzi BC; Caspar C; Albrecht S; von Moos R; Ruhstaller T
Onkologie; 2009 Dec; 32(12):724-30. PubMed ID: 20016233
[TBL] [Abstract][Full Text] [Related]
19. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
20. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
